Abstract: The present invention relates to the novel formulation for sustained or delayed release of rohitukine-rich Dysoxylum binectariferum extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract/fraction of rohitukine-rich Dysoxylum binectariferum with polymers has resulted in a sustained release of the extract or fraction over a period of 16-24 hrs. The said formulations are useful in the treatment of inflammatory diseases.

Abstract: The present invention relates to the novel formulation for sustained or delayed release of rohitukine-rich Dysoxylum binectariferum extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract/fraction of rohitukine-rich Dysoxylum binectariferum with polymers has resulted in a sustained release of the extract or fraction over a period of 16-24 hrs. The said formulations are useful in the treatment of inflammatory diseases.

Abstract: The present invention is related to a novel gastroretentive swellable oral dosage form for sustained or delayed release of bergenin, a active constituent of Bergenia ciliata extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract of bergenin-rich Bergenia ciliata with polymers has resulted in a sustained release of extract in the stomach over a period of 16-24 hrs. The said formulations are useful for the treatment of inflammatory diseases.

Abstract: The present invention is related to the novel solid dispersion formulations of an anticancer compound of formula A and a process for preparing the same wherein the anticancer compound is formulated with hydrophilic polymer. The said formulation showed enhanced dissolution of the anticancer compound and improved in-vivo anticancer activity. The said formulations are useful for the treatment of various types of cancer.

Abstract: The present invention relates to the furanochalcone class of compounds of general formula A. The present invention particularly relates to the synthesis of furanochalcones and their CYP1A1, CYP1A2 and CYP1B1 inhibitory activity. In addition, the invention relates to the prevention or treatment of cancer caused by polyaromatic hydrocarbons (PAHs), 4-nitroquinoline-1-oxide, and N-nitroso-N-methylurea, heterocyclic amines, estrogen and 17?-estradiol, resulting from the inhibition of CYP1A1, CYP1A2 and CYP1B1 enzymes.

Abstract: The present invention relates to the novel formulation for sustained or delayed release of rohitukine-rich Dysoxylum binectariferum extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract/fraction of rohitukine-rich Dysoxylum binectariferum with polymers has resulted in a sustained release of the extract or fraction over a period of 16-24 hrs. The said formulations are useful in the treatment of inflammatory diseases.

Abstract: The present invention is related to the novel oral dosage form for sustained release of crocin-1, a active constituent of Crocus sativus extract or fraction and a process for preparing the same wherein the extract is wet-granulated using excipients, biodegradable polymers and/or non-biodegradable polymers alone or in combination. The said formulations are useful for the treatment of chronic inflammatory diseases wherein NLRP3 inflammasome is involved.

Abstract: The present invention is related to a novel gastroretentive swellable oral dosage form for sustained or delayed release of bergenin, a active constituent of Bergenia ciliata extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract of bergenin-rich Bergenia ciliata with polymers has resulted in a sustained release of extract in the stomach over a period of 16-24 hrs. The said formulations are useful for the treatment of inflammatory diseases.

Abstract: The present invention relates to fused pyrimidines of formulae I and II wherein, R1, R2 are as herein described. The present invention particularly relates to isoform selective PI3K? inhibition and their medicinal use as anticancer agents.

Abstract: The present invention relates to fused pyrimidines of formulae I and II wherein, R1, R2 are as herein described. The present invention particularly relates to isoform selective PI3K? inhibition and their medicinal use as anticancer agents.

Abstract: The present invention relates to the alkylidene phosphonate esters of formula I wherein, R1 is selected from a group consisting of hydrogen or alkyl group; R2 is selected from a group consisting of hydrogen, hydroxy, alkyl, alkoxy, nitro, halogen, amino, N-substituted alkylamino; alkyl group is selected from a group consisting of methyl, ethyl and isopropyl; Ar is selected from a group consisting of aryl, substituted aryl, fused aryl, heteroaryl, and substituted heteroaryl. The present invention particularly relates to synthesis and p-glycoprotein induction activity of the alkylidene phosphonate esters. In addition, the invention relates to methods of using compounds for treating or preventing Alzheimer's disease.

Abstract: The present invention relates to the polyprenylated phloroglucinol compounds of formulae I and II. The present invention also provides synthesis and p-glycoprotein induction activity of the alkyl- and acyl-polyprenylated phloroglucinol compounds. Further, use of the compounds as p-glycoprotein inducers and methods of treatment of Alzheimer's disease using compounds of the invention are also provided.

Abstract: The present invention relates to the N-substituted beta-carbolinium compounds of general formula A and formulae I and II wherein, R1 and R2 groups are selected from halogens or trifluoromethyl; R3 group is selected from hydrogen or methyl; Ar is selected from aryl and heteroaryl, X is selected from halogens; and R1 and R2 groups may be attached to any position on ring E. The present invention particularly relates to synthesis and p-glycoprotein induction activity of the N-substituted beta-carbolinium compounds. In addition, the invention relates to methods of using compounds for treating or preventing Alzheimer's disease.

Abstract: A pharmaceutical composition for the treatment of multi-drug resistant infections includes an antimicrobial agent in combination the benzopyrano[3,4-b][1]benzopyran-12(6H)-one class of compound boeravinone B of Formula 1: The bio-efficacy of anti-infective drugs can be potentiated, when used in combination with boeravinone B. Boeravinone B can overcome the resistance or multi-drug resistance developed by bacteria against quinolone, mupirocin and macrolide class of anti-bacterial agents via inhibition of bacterial efflux pumps. Thus, the compositions can be used to treat or prevent drug-resistant bacterial diseases.

Abstract: The present invention relates to the rohitukine (5,7-dihydroxy-8-(3-hydroxy-1-methyl-piperidin-4-yl)-4H-chromen-4-ones) analogs of formula A and pharmaceutically acceptable salts thereof. In addition, the invention relates to pharmaceutically acceptable compositions comprising at least one such compound, and methods of using the compounds for treating or preventing various proliferative disorders such as melanoma, leukemia, breast cancer and prostate cancer etc. [insert Formula A here] wherein, n=0 or 1, when n=1, the dotted line indicates the double bond.

Abstract: The present invention relates to the compounds of formula I wherein R is as herein described. The present invention particularly relates to synthesis and antiproliferative activity of 10-substituted colchicinoids. Compounds of the invention can be used for prevention or in the treatment of cancer disease.

Abstract: The present invention relates to the N-substituted beta-carbolinium compounds of general formula A and formulae I and II wherein, R1 and R2 groups are selected from halogens or trifluoromethyl; R3 group is selected from hydrogen or methyl; Ar is selected from aryl and heteroaryl, X is selected from halogens; and R1 and R2 groups may be attached to any position on ring E. The present invention particularly relates to synthesis and p-glycoprotein induction activity of the N-substituted beta-carbolinium compounds. In addition, the invention relates to methods of using compounds for treating or preventing Alzheimer's disease.

Abstract: The present invention relates to the polyprenylated phloroglucinol compounds of formulae I and II. The present invention also provides synthesis and p-glycoprotein induction activity of the alkyl- and acyl-polyprenylated phloroglucinol compounds. Further, use of the compounds as p-glycoprotein inducers and methods of treatment of Alzheimer's disease using compounds of the invention are also provided.

Abstract: The present invention relates to the alkylidene phosphonate esters of formula I wherein, R1 is selected from a group consisting of hydrogen or alkyl group; R2 is selected from a group consisting of hydrogen, hydroxy, alkyl, alkoxy, nitro, halogen, amino, N-substituted alkylamino; alkyl group is selected from a group consisting of methyl, ethyl and isopropyl; Ar is selected from a group consisting of aryl, substituted aryl, fused aryl, heteroaryl, and substituted heteroaryl. The present invention particularly relates to synthesis and p-glycoprotein induction activity of the alkylidene phosphonate esters. In addition, the invention relates to methods of using compounds for treating or preventing Alzheimer's disease.

Abstract: A pharmaceutical composition for the treatment of multi-drug resistant infections includes an antimicrobial agent in combination the benzopyrano[3,4-b][1]benzopyran-12(6H)-one class of compound boeravinone B of Formula 1: The bio-efficacy of anti-infective drugs can be potentiated, when used in combination with boeravinone B. Boeravinone B can overcome the resistance or multi-drug resistance developed by bacteria against quinolone, mupirocin and macrolide class of anti-bacterial agents via inhibition of bacterial efflux pumps. Thus, the compositions can be used to treat or prevent drug-resistant bacterial diseases.